The HDL criterion for MetALD can misclassify patients with cirrhosis [0.03%]
用于代谢性酒精性肝病的HDL标准可能误诊肝硬化患者
Gene Y Im,Ashish Bibireddy,Smruti Rath
Gene Y Im
Revealing Bias in Feature Importance through PLS-DA: A Critical Examination of Machine Learning Applications in Chronic Liver Disease [0.03%]
通过PLS-DA揭示特征重要性的偏倚：对机器学习在慢性肝病应用中的批判性审查
Yoshiyasu Takefuji
Yoshiyasu Takefuji
Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis [0.03%]
卡维地洛与普萘洛尔用于代偿期和失代偿期肝硬化的患者预防再发及死亡的比较优势
Jose Ignacio Fortea,Edilmar Alvarado-Tapias,Benedikt Simbrunner et al.
Jose Ignacio Fortea et al.
Background and aims: Data on the effectiveness of classical non-selective beta-blockers (cNSBB, i.e., propranolol and nadolol) versus carvedilol in patients with cirrhosis are scarce. The present study aimed to compare th...
Antonio Segovia-Zafra,M Isabel Lucena,Raul J Andrade
Antonio Segovia-Zafra
Long-term use of tenofovir disoproxil fumarate and increased fracture risk in elderly patients with chronic hepatitis B: A Sensitivity Analysis Quantifying Effect of Unmeasured Confounding factors on Observational Associations [0.03%]
替诺福韦酯长期用于老年慢性乙肝患者与骨折风险增加：一种敏感性分析，量化未测量的混淆因素对观察结果的影响
Guiying Gao,Jie Guo,Guo Yu et al.
Guiying Gao et al.
Assessment of methods in E1E2 versus E2 immunogen studies for HCV vaccine research [0.03%]
HCV疫苗研究中E1E2与E2免疫原试验方法评估
Chenxi Wang,Huichuan Tian,Jin Shang
Chenxi Wang
Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study [0.03%]
优化抗病毒预防策略：一项真实世界研究的见解与反思
Shanshan Liu,Xinmin Deng,Xiaofeng Lv
Shanshan Liu
Amedeo Lonardo,Giovanni Targher
Amedeo Lonardo
Maito Suoh,Saeed Esmaili,Mohammed Eslam et al.
Maito Suoh et al.
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma [0.03%]
欧洲肝脏研究学会肝细胞癌管理指南
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;European Association for the Study of the Liver
Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers. Advances in diagnostic and therapeutic tools, along with improved und...
Practice Guideline
Journal of hepatology. 2024 Dec 16:S0168-8278(24)02508-X. DOI:10.1016/j.jhep.2024.08.028 2024